ducovest

TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 49.25

Change

0.00 (0.00)%

Market Cap

USD 1.93B

Volume

0.36M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Company Website : https://www.tarsusrx.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

 USD 126.52B
REGN Regeneron Pharmaceuticals Inc

N/A

 USD 69.68B
ARGX argenx NV ADR

N/A

 USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

N/A

 USD 30.51B
ONC BeiGene, Ltd.

N/A

 USD 26.35B
RPRX Royalty Pharma Plc

N/A

 USD 19.31B
SMMT Summit Therapeutics PLC

N/A

 USD 14.57B
INSM Insmed Inc

N/A

 USD 12.52B
INCY Incyte Corporation

N/A

 USD 11.72B
BMRN Biomarin Pharmaceutical Inc

N/A

 USD 11.50B

ETFs Containing TARS

SLX VanEck Steel ETF 5.68 % 0.56 %

N/A

 N/A
XME SPDR® S&P Metals and Min.. 5.05 % 0.35 %

N/A

 N/A
BASE:CA Evolve Global Materials &.. 4.98 % 0.00 %

N/A

 CAD 0.05B
BASE-B:CA Evolve Global Materials &.. 4.98 % 0.00 %

N/A

 CAD 0.08B
XPH SPDR® S&P Pharmaceutical.. 4.10 % 0.35 %

N/A

 N/A
FXZ First Trust Materials Alp.. 3.93 % 0.64 %

N/A

 N/A
PYZ Invesco DWA Basic Materia.. 3.75 % 0.60 %

N/A

 USD 0.05B
SMLL Harbor ETF Trust 3.51 % 0.28 %

N/A

 N/A
PILL Direxion Daily Pharmaceut.. 3.35 % 0.98 %

N/A

 N/A
PICK iShares MSCI Global Metal.. 1.74 % 0.39 %

N/A

 USD 0.31B
IJJ iShares S&P Mid-Cap 400 V.. 1.19 % 0.25 %

N/A

 USD 6.97B
MDYV SPDR® S&P 400 Mid Cap Va.. 1.18 % 0.15 %

N/A

 N/A
SPY4:LSE SPDR® S&P 400 US Mid Cap.. 0.57 % 0.00 %

N/A

 N/A
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.57 % 0.00 %

N/A

 N/A
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.57 % 0.00 %

N/A

 N/A
IJH iShares Core S&P Mid-Cap .. 0.57 % 0.07 %

N/A

 USD 83.09B
IWC iShares Micro-Cap ETF 0.55 % 0.60 %

N/A

 N/A
SMLF iShares MSCI USA Small-Ca.. 0.54 % 0.30 %

N/A

 N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 0.00 % 0.15 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.05% 71% C- 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.05% 71% C- 52% F
Trailing 12 Months  
Capital Gain 51.82% 90% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.82% 90% A- 90% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 22.77% 70% C- 79% B-
Dividend Return 22.77% 70% C- 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 67.85% 50% F 27% F
Risk Adjusted Return 33.57% 88% B+ 67% D+
Market Capitalization 1.93B 89% A- 80% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector